When scores for tumour cytoplasm and stromal JAK2 were combined, patients high for the marker in both locations had significantly reduced prognosis (HR = 1.550, 95% CI: 1.099–2.187, log rank p = 0.013) (Figure 3J). Here, JAK2 is linked to neoplasm.